Synairgen (SNG)

 

SNG Share PerformanceMore

52 week high37.9000 11/08/16
52 week low7.0000 27/04/17
52 week change -20.5000 (-70.69%)
4 week volume520,745 27/06/17

Media for (SNG)

Presenter: Richard Marsden, CEO
11/11/2014
Presenter: Richard Marsden
08/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Synairgen shareholders pass all resolutions at AGM

Synairgen has confirmed that all resolutions were passed by shareholders at today's Annual General Meeting. At 1:01pm: (LO...

Result of AGM

RNS Number: 4493J Synairgen plc 28 June 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Result of Annual General Meeting Southampton, UK - 28 June 2017: Synairgen (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce that all resolutions proposed at its Annual General Meeting, held earlier today, were duly...

Posting of Annual Report and Notice of AGM

RNS Number: 0559H Synairgen plc 05 June 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Posting of Annual Report and Notice of AGM Southampton, UK - 5 June 2017: Synairgen (LSE: SNG), the respiratory drug discovery and development company, announces that on 2 June 201 7 it posted its full Audited Report and Accounts for the twelve month...

Preliminary Results

RNS Number: 3540F Synairgen plc 17 May 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Preliminary statement of results for the year ended 31 December 2016 Southampton, UK - 17 May 2017: Synairgen (LSE: SNG), the respiratory drug discovery and development company, today announces its preliminary statement of audited results for the year en...

US tax reform plans and ex-dividends push FTSE lower

Investors were disappointed with a lack of detail on US President Donald Trump's tax reform plans, while stocks going ex-d...

Synairgen updates on AZD9412

Synairgen (SNG) said its AZD9412 study did not meet AstraZeneca's predefined criteria for progression, and it had elected ...

AZD9412 Update

RNS Number: 4767D Synairgen plc 27 April 2017 Press release Synairgen plc ('Synairgen' or the 'Company') AZD9412 Update Cold infections did not affect trial patients' asthma in the INEXAS study as much as predicted, meaning that the drug's effects on severe exacerbations could not be determined Treatment with AZD9412 switched on antiviral responses in the lu...

Holding(s) in Company

RNS Number: 5177A Synairgen plc 27 March 2017 Synairgen plc ('Synairgen' or the 'Company') Holding in Company Southampton, UK,: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it received notice on 24 March 2017 that Leonard Licht, a private investor, now holds 3,700,000 ordinary shares of 1 pence each in...

Fundamental DataMore

EPS-3.08
Dividend yield0 %

Equity Research (SNG)

edison investment research
Synairgen
14/07/2014
The recent exclusive global deal with AstraZeneca, potentially worth $230m, to in-license SNG001 for the treatment of asthma is a strong validation of Synairgen’s in-vitro cell-based approach using...

Latest discussion posts More

  • Shame.

    Synairgen plc ('Synairgen' or the 'Company') AZD9412 Update ? Cold infections did not affect trial patients' asthma in the INEXAS study as much as predicted, ...
    27-Apr-2017
    Disorder
  • Re: :-)

    Yes very encouraging. Also waiting for the akzo decision or not? Thanks for the tippage. Up a great deal again!
    10-Mar-2017
    high blood pressure1
  • Re: :-)

    Yes very encouraging. Also waiting for the akzo decision or not? 5th and for the tippage. Up a great deal again!
    10-Mar-2017
    high blood pressure1

Users' HoldingsMore

Users who hold Synairgen also hold..
PREMIER OIL29%
JUBILEE PLAT.19%
ID:ISIN:VGG9828A119419%
LLOYDS GRP.16%
AVANTI COMM.16%

Codes & Symbols

ISINGB00B0381Z20
SymbolsSNG, LSE:SNG, SNG.L, SNG:LN, LON:SNG, XLON:SNG